Raw Material CAS 1611493-60-7 Bictegravir Powder API Bictegravir Pharmaceutical Bictegravir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Bictegravir
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Bictegravir
• Appearance: off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Antiviral
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 1611493-60-7
• Mf: C21h18f3n3o5
• MW: 449.4
• Density: 1.62+-0.1 g/cm3(Predicted)
• Boiling Point: 682.5+-55.0 C at 760 Mmhg
• Refractive Index: 1.664
• Flash Point: 366.6+-31.5 C
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

Raw Material CAS 1611493-60-7 Bictegravir Powder API Bictegravir Pharmaceutical Bictegravir

 

Product Description

Product Details

Product Name	Bictegravir
Appearance	Off-white powder
Application	Antiviral
CAS No.	1611493-60-7
MF	C21H18F3N3O5

Biktigravir (BIC) is a second-generation integrase chain transfer inhibitor (INSTI), which has been approved for use in fixed-dose combination with emtricitabine and tenofovir alafenamiChemicalbookde for HIV treatment.  The first-generation resistant strains have effective antiviral activity INSTIs in vitro.

Application & Function

Function of Bictegravir
Biktigravir mainly clears the liver through cytochrome P4503A4 (CYP3A4) oxidation and UDP-glucosyltransferase 1A1 (UGT1A1) glucuronidation.  Therefore, due to the significant reduction of Biktegravir blood Chemicalbook clear exposure, the use of potent inducers of UGT1A1 and CYP3A4 (such as rifamycin/anticonvulsants) should be avoided.  Chelating with polyvalent cations can reduce absorption;  otherwise, there is little interaction between the drug and the drug.
Application of Bictegravir
Bictegravir (BIC) is a new type of integrase inhibitor, a new research drug of integrase inhibitor discovered by scientists.  As of June 2016, Bictegravir (BIC) was used as a single-tablet regimen in combination with Tenofovir Alafe Chemicalbooknamide Fumarate (TAF) and Emtricitabine (FTC) for the treatment of HIV-1 infection, BIC/ In the 48-week Phase III clinical trial of FTC/TAF, it was found that it has a high virus inhibition rate, which can inhibit 97% of the virus, and no adverse reactions have been found.  It is less toxic to bone and kidney, and may become the most Competitive anti-HIV drugs.

Specification